TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29243546
Drug: Cancer therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer therapy
Study: 29243546
Drug: Long-term prevention
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term prevention medications
Study: 29243546
Drug: Heart medication/anti-hypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart medication/anti-hypertensives
Study: 29243796
Drug: Myo-inositol pre-treatment
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol pre-treatment in women undergoing IVF
Study: 29244957
Drug: ENPP1 mutation
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENPP1 mutation treatment (specific intervention details not provided)
Study: 29245310
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg qd) plus Irinotecan (340 mg/m or 125 mg/m depending on use of enzyme-inducing antiepileptic drugs) for 6 cycles, followed by maintenance with apatinib.
Study: 29246128
Drug: Maternal 25(OH)D
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal 25(OH)D concentration during pregnancy (≥ 80 nmol/L)
Study: 29246128
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test results
Study: 29246150
Drug: Low-dose lymphocyte
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lymphocyte immunotherapy
Study: 29246151
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (primary CVD prevention)
Study: 29246151
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (secondary CVD prevention)
Study: 29246803
Drug: Venetoclax (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (starting at 20 mg per day with stepwise dose ramp-up over 5 weeks to 400 mg per day; accelerated dosing schedule for rapidly progressing disease to 400 mg per day by week 3)
Study: 29246900
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy with AMT-060 (AAV5 vector with liver-specific promoter)
Study: 29246909
Drug: Ultimaster drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultimaster drug-eluting stent
Study: 29246916
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ticagrelor without stenting for ≤1 month
Study: 29247021
Drug: Ulixertinib (BVD-523)
Normalized name: BVdU
DrugBank: Ulixertinib (DB13930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulixertinib (BVD-523) at a recommended phase II dose (RP2D) of 600 mg twice daily
Study: 29247063
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and systemic tracer of vascular endothelial growth factor A
Study: 29247830
Drug: AUY922 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUY922 (70 mg/m weekly intravenous)
Study: 29248236
Drug: Bipolar androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar androgen therapy (BAT) with intramuscular testosterone cipionate 400 mg every 28 days until progression and continued luteinising hormone-releasing hormone agonist therapy.
Study: 29248236
Drug: Rechallenge with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rechallenge with oral enzalutamide 160 mg daily after progression on BAT.
Study: 29249180
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine
Study: 29249202
Drug: Model projections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model projections with 30% treatment coverage (TC) rate
Study: 29250743
Drug: Early tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early tapering of immunosuppressive agents
Study: 29250743
Drug: Routine tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine tapering of immunosuppressive agents
Study: 29251556
Drug: Ambrisentan and
Normalized name: ambrisentan and tadalafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan and tadalafil combination therapy
Study: 29252124
Drug: M6620 (ATR
Approvals — FDA: no, EMA: no, PMDA: no
Description: M6620 (ATR inhibitor) + Topotecan (1.25 mg/m²)
Study: 29253081
Drug: Cohort A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort A: Four cycles of dose-dense doxorubicin and cyclophosphamide, followed by 12 doses of standard paclitaxel plus four cycles of trastuzumab and pertuzumab.
Study: 29253081
Drug: Cohort A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort A: Pertuzumab, trastuzumab, and chemotherapy.
Study: 29253081
Drug: Cohort B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort B: Pertuzumab, trastuzumab, and chemotherapy.
Study: 29253097
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg) plus Lamivudine (300 mg)
Study: 29254506
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interleukin-2 therapy (IL-2)
Study: 29254856
Drug: Single fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single fraction of multi-catheter interstitial high-dose rate brachytherapy (16 Gy)
Study: 29255413
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lifestyle ± metformin without intervention)
Study: 29257710
Drug: PT2385 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT2385 at 800 mg twice per day (RP2D)
Study: 29258560
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (4 hours each weekday for 10 treatment days)
Study: 29258618
Drug: Autologous tumor-derived
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor-derived autophagosome vaccine (DRibbles)
Study: 29258674
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus ipilimumab followed by surgery
Study: 29258674
Drug: Standard preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preoperative chemotherapy (platinum doublet regimen) followed by surgery
Study: 29259073
Drug: Panitumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (6 mg/kg IV every 14 days)
Study: 29260460
Drug: Second-line antidiabetic
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line antidiabetic treatment
Study: 29260603
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach, 12 sessions, twice a week, with an additional session for parents' orientation.
Study: 29261402
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) bronchodilator inhalation with salbutamol 2.5 mg/ipratropium bromide 500 μg solution
Study: 29261402
Drug: Oral bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bronchodilator inhalation with salbutamol 2.5 mg/ipratropium bromide 500 μg solution
Study: 29263019
Drug: Ranolazine (500-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (500-1000 mg twice a day)
Study: 29263061
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) in subjects with chronic kidney disease
Study: 29263061
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) under dialysis conditions
Study: 29263061
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) under nondialysis conditions
Study: 29263070
Drug: Alalevonadifloxacin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alalevonadifloxacin (1,000 mg twice daily for 5 days)
Study: 29264930
Drug: No extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: No extended treatment
Study: 29268758
Drug: Pamphlet provided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamphlet provided by reception staff addressing barriers and enablers to registration, along with an Internet-enabled tablet for registration.
Study: 29269796
Drug: Intravenous pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pentamidine at 4 mg/kg (maximum 300 mg)
Study: 29270208
Drug: Proactive telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive telephone support (daily calls initiated by a breastfeeding support team)
Study: 29270487
Drug: Fresolimumab 1
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresolimumab 1 mg/kg
Study: 29270487
Drug: Fresolimumab 4
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresolimumab 4 mg/kg
Study: 29270685
Drug: BoNT-A treatment
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT-A treatment
Study: 29270781
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg maximum dose)
Study: 29270787
Drug: FDG PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG PET/CT at baseline (PET0), after induction (PET-AI), and end of treatment (PET-EoT)
Study: 29272364
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) dose-escalation cohort, 1.8 mg/kg IV every 3 weeks for two cycles, escalated to 2.4 mg/kg for patients with stable disease or partial response.
Study: 29272364
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) standard/fixed-dose cohort.
Study: 29272443
Drug: Monthly DHA-PQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly DHA-PQ (2880 mg PQ)
Study: 29272443
Drug: Weekly DHA-PQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly DHA-PQ (960 mg PQ)
Study: 29272443
Drug: Low-dose daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose daily DHA-PQ (320 or 160 mg PQ)
Study: 29272443
Drug: Low daily
Normalized name: SODIUM FLUORIDE 2.43 mg in 1 g DENTAL PASTE, DENTIFRICE [Auraglow Daily]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low daily DHA-PQ dosing
Study: 29273054
Drug: NG12-1 vasoconstrictor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG12-1 vasoconstrictor, applied topically, 30 daily treatments before radiotherapy.
Study: 29273054
Drug: Control area
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control area (no treatment).
Study: 29274193
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg once daily for 6 weeks
Study: 29274193
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg once daily for 8 weeks
Study: 29274193
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events reported in 63.2% of patients (43/68), mainly grade 1/2, none led to treatment discontinuation.
Study: 29275146
Drug: Ciprofloxacin, levofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, levofloxacin, or fosfomycin (antibiotic prophylaxis)
Study: 29275946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of specific ECG abnormalities
Study: 29276022
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.2 mg/kg or 1.8 mg/kg) plus bendamustine (70 mg/m2)
Study: 29276022
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.8 mg/kg) plus bendamustine (80 mg/m2)
Study: 29276625
Drug: Epicardial transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicardial transplantation of atrial appendage micrografts in a fibrin gel covered with a tissue-engineered ECM sheet
Study: 29277374
Drug: Aphasia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aphasia therapy with aerobic exercise via bicycle ergometer (n = 5)
Study: 29277374
Drug: Aphasia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aphasia therapy with stretching (n = 2)
Study: 29277374
Drug: Aphasia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aphasia therapy alone (Block 1)
Study: 29279281
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.5 mL PCV13 in previously vaccinated subjects (n=284)
Study: 29279281
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of 0.5 mL PCV13 in previously vaccinated subjects (n=288)
Study: 29280355
Drug: 50, 125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50, 125, 300, or 600 mg of testosterone enanthate weekly injections
Study: 29280355
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg dutasteride daily
Study: 29280762
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin at 1.2 mg/kg with AVD (doxorubicin, vinblastine, dacarbazine)
Study: 29281086
Drug: Antiplatelet (AP)
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet (AP) monotherapy
Study: 29281086
Drug: Anticoagulant (AC)
Normalized name: CPDA-1 Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulant (AC) monotherapy
Study: 29281086
Drug: AP monotherapy
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP monotherapy
Study: 29281086
Drug: AC monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC monotherapy
Study: 29281086
Drug: AP +
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP + AC and no antithrombotic therapy
Study: 29282024
Drug: Emotion regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion regulation individual therapy (ERITA) for 12 weeks
Study: 29282032
Drug: Riociguat adjusted
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riociguat adjusted from 1 mg three times daily (tid) to a maximum of 2.5 mg tid
Study: 29282090
Drug: Tofacitinib (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (5.0 mg BID for Cohort 1, 2.5 mg BID for Cohort 2, 3.0 mg BID for Cohort 3)
Study: 29282090
Drug: Tofacitinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (oral solution, grape flavor)
Study: 29282090
Drug: Tofacitinib (multiple-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (multiple-dose, twice daily for 5 days)
Study: 29282099
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for six months
Study: 29282271
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT (LDCT) during yearly screening rounds for 3 years plus a 1-year follow-up.
Study: 29282676
Drug: Ambrisentan (Volibris
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (Volibris tablet 2.5 mg)
Study: 29284010
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg administered every 2 weeks for up to 2 years or until disease progression/unacceptable toxicity
Study: 29284510
Drug: Low-dose, prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, prophylactic naloxone infusion
Study: 29285038
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and Gemcitabine (Neoadjuvant Chemotherapy)
Study: 29285668
Drug: Cabazitaxel 20
Normalized name: cabazitaxel 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel 20 mg/m² administered in second-(or later) setting, median of two cycles.
Study: 29391382
Drug: bDMARD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: bDMARD treatment
Study: 29288237
Drug: Genomics-driven precision
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomics-driven precision medicine
Study: 29288911
Drug: Perampanel secondary
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel secondary monotherapy
Study: 29288911
Drug: Perampanel adjunctive
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel adjunctive treatment
Study: 29289757
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapy
Study: 29290515
Drug: Fixed airflow
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed airflow obstruction (FAO) defined as post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity ≤70%
Study: 29292064
Drug: DREAMS 2G
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: DREAMS 2G (drug-eluting absorbable metal scaffold)
Study: 29292843
Drug: Ontuxizumab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontuxizumab at 12 mg/kg
Study: 29293893
Drug: Fosmidomycin-piperaquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmidomycin-piperaquine (30 mg/kg twice daily for fosmidomycin and 16 mg/kg once daily for piperaquine for 3 days)
Study: 29296710
Drug: Epstein-Barr virus
Normalized name: Epstein-Barr virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epstein-Barr virus (EBV) DNA in cell-free blood 8 days after initiation of therapy
Study: 29296707
Drug: Posttransplant cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttransplant cyclophosphamide (PT-Cy) at 0 mg/kg in cohort 1
Study: 29296707
Drug: Posttransplant cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttransplant cyclophosphamide (PT-Cy) at 50 mg/kg in cohort 2
Study: 29296707
Drug: Posttransplant cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttransplant cyclophosphamide (PT-Cy) at 100 mg/kg in cohort 3
Study: 29296758
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (InO) 1.2 mg/m²
Study: 29296758
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (InO) 1.6 mg/m²
Study: 29296758
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (InO) 1.8 mg/m²
Study: 29296838
Drug: Sonidegib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib (200 mg/day, 400 mg/day, 600 mg/day) for up to 12 cycles of 28 days each
Study: 29296873
Drug: Bortezomib maintenance
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib maintenance therapy after tandem autologous/allogeneic hematopoietic cell transplantation
Study: 29296873
Drug: High-dose conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose conditioning regimen with melphalan 200 mg/m2 for autologous hematopoietic cell transplantation
Study: 29298867
Drug: dezamizumab (fully
Approvals — FDA: no, EMA: no, PMDA: no
Description: dezamizumab (fully humanized monoclonal IgG1 anti-SAP antibody)
Study: 29298867
Drug: miridesap (small-molecule
Approvals — FDA: no, EMA: no, PMDA: no
Description: miridesap (small-molecule drug)
Study: 29299030
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of warfarin in low-risk patients with sustained sinus rhythm
Study: 29300435
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of drugs used or causative drug use
Study: 29301580
Drug: PEGASYS® (pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGASYS® (pegylated interferon alfa-2a from Roche Pharmaceutical)
Study: 29302336
Drug: Acellular bioscaffolds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular bioscaffolds composed of mammalian extracellular matrix (ECM) implanted with aggressive and early physical therapy
Study: 29302336
Drug: Acellular bioscaffolds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular bioscaffolds with physical therapy
Study: 29304833
Drug: Selinexor (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (80 mg/day) in combination with high-dose cytarabine and mitoxantrone (HiDAC/Mito)
Study: 29305501
Drug: Lactobacillus supplementation
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus supplementation or intervention, specific dosage and duration not mentioned
Study: 29305552
Drug: Venetoclax (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (initiated at 20 mg daily, ramped up to 400 mg daily)